Prevent Cognitive Decline in GBA-associated Parkinson's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

May 31, 2031

Conditions
Parkinson's Disease
Interventions
DRUG

Prasinezumab

Prasinezumab 1500 mg monthly infusion

DRUG

Sodium Chloride

Saline infusion (0,9 % sodium chloride) monthly infusion

Trial Locations (8)

Unknown

Sorbonne University, Pitié-Salpêtrière Hospital, Paris

University Hospital Tubingen, Tübingen

University of Brescia and ASST Spedali Civili of Brescia, Brescia

Fondazione IRCCS Ca' Granda Policlinico Hospital, Milan

University of Luxemburg, Luxembourg

Hospital Universitario HM Puerta del Sur, Madrid, Madrid

Karolinska University of Stockholm, Stockholm

University of Oxford, Oxford

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER